304 Appendices 340. Noguchi M, Minami Y, Iijima T, Matsuno Y. Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria. Pathol Int. 2005;55(1):8-13. doi:10.1111/j.1440-1827.2005.01782.x 341. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. Travis W., Brambilla E, Burke AP, Marx A, Nicholson AG, eds. J Thorac Oncol. 2015;10(9):1243-1260. doi:10.1097/JTO.0000000000000630 342. Blaauwgeers H, Damhuis R, Lissenberg-Witte BI, de Langen AJ, Senan S, Thunnissen E. A Population-Based Study of Outcomes in Surgically Resected T3N0 Non–Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm. J Thorac Oncol. 2019;14(3):459-467. doi:10.1016/j.jtho.2018.10.164 343. Filipello F, Blaauwgeers H, Lissenberg-Witte B, et al. 3-dimensional reflection aids in understanding the fog of 2-dimentional pattern recognition in pulmonary adenocarcinomas with emphasis on collapsed adenocarcinoma in situ and a proposal for a revised classification. 2023;submitted. 344. Inafuku K, Yokose T, Ito H, et al. Should Pathologically Noninvasive Lung Adenocarcinoma Larger Than 3 cm Be Classified as T1a? Ann Thorac Surg. 2019;108(6):1678-1684. doi:10.1016/j.athoracsur.2019.06.055 345. Strand TE, Rostad H, Strøm EH, Hasleton P. The percentage of lepidic growth is an independent prognostic factor in invasive adenocarcinoma of the lung. Diagn Pathol. 2015;10(1):1-7. doi:10.1186/s13000-015-0335-8 346. Ji H, Liu Q, Chen Y, et al. Combined model of radiomics and clinical features for differentiating pneumonic-type mucinous adenocarcinoma from lobar pneumonia: An exploratory study. Front Endocrinol (Lausanne). 2023;13(January):1-12. doi:10.3389/ fendo.2022.997921 347. Decavèle M, Parrot A, Duruisseaux M, et al. Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study. J Thorac Dis. 2022;14(8):2812-2825. doi:10.21037/jtd-22-12 348. Huo J wen, Huang X tao, Li X, Gong J wei, Luo T you, Li Q. Pneumonic-type lung adenocarcinoma with different ranges exhibiting different clinical, imaging, and pathological characteristics. Insights Imaging. 2021;12(1). doi:10.1186/s13244-021-01114-2 349. Shui Y, Wang H. Metagenomic next-generation sequencing as an unconventional approach to warn of tumor cells in a patients with non-mucinous pneumonic-type lung adenocarcinoma: Case report. Med (United States). 2022;101(51). doi:10.1097/MD.0000000000032448 350. Nakamura S, Ashizawa K, Fukuda M, Uetani M. Mucinous and nonmucinous pneumonictype adenocarcinoma: CT classification and clinical outcome. J Clin Oncol. 2011;29(15\_ suppl):e18073-e18073. doi:10.1200/jco.2011.29.15\_suppl.e18073 351. Stewart LA, Pignon JP. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 1995;311(7010):899-909. doi:10.1016/0169-5002(96)85918-6 352. Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: Systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009;4(11):13801388. doi:10.1097/JTO.0b013e3181b9ecca 353. Provencio M, Calvo V, Romero A, Spicer JD, Cruz-Bermúdez A. Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. Am Soc Clin Oncol Educ B. 2022;(42):711-728. doi:10.1200/edbk_358995 354. Blumenthal GM, Bunn PA, Chaft JE, et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018;13(12):1818-1831. doi:10.1016/j. jtho.2018.09.017
RkJQdWJsaXNoZXIy MTk4NDMw